Rhumbline Advisers Eye Point Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 89,560 shares of EYPT stock, worth $550,794. This represents 0.0% of its overall portfolio holdings.
Number of Shares
89,560
Previous 77,117
16.14%
Holding current value
$550,794
Previous $616,000
8.28%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding EYPT
# of Institutions
156Shares Held
72.4MCall Options Held
187KPut Options Held
225K-
Cormorant Asset Management, LP Boston, MA8.33MShares$51.2 Million4.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.78MShares$41.7 Million2.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.75MShares$35.4 Million0.08% of portfolio
-
Franklin Resources Inc San Mateo, CA4.14MShares$25.4 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$23.4 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $210M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...